Stanford researchers have transplanted laboratory-grown human cortical tissue into newborn genetically engineered mice that lack most of the cerebral cortex and hippocampus, producing an experimental model in which the grafted human tissue came to occupy more than 90% of cortical tissue volume after three months.
The work, announced Sept. 16 by Stanford Medicine alongside online publication in Nature, is a substantial advance in efforts to study human neural cells inside a living nervous system. It may offer a way to examine how patient-derived cells respond to injury or candidate interventions. But the animals are mice, not rats, and the experiment did not create human brains in mice, establish human-like cognition or test a treatment in people.
What the researchers transplanted
The team grew cortical organoids from human stem cells. Organoids are three-dimensional collections of cells that can reproduce selected features of a developing organ; they are not miniature, complete brains. The human donors whose cells were used in this experiment had consented to transplantation of their cells into animals, Stanford said.
Researchers implanted the organoids into two-day-old “apallial” mice, engineered to have an enlarged space because they lack most of the cortex and hippocampus. The grafts survived, expanded and formed connections with the host mouse’s brain and spinal cord, according to Stanford. The institution calls the animals xenocortical mice, using a term for tissue transferred across species.
The spatial arrangement was the key methodological change from Stanford’s 2022 work, which transplanted human cortical organoids into newborn rats with intact brains. An intact brain leaves limited room for a graft to expand. Removing much of the recipient’s cortex gave the human tissue far more physical space, allowing researchers to observe it over a longer period and at a larger scale.
Specialist reporting by Inside Precision Medicine said 29 transplanted animals were evaluated for engraftment and that 86.2% showed successful engraftment. The public accounts did not provide a full account of statistical analyses, behavioral protocols or the degree of variation among individual grafts, details that will be important in assessing how consistently the model performs.
Why “half-human” is an imprecise label
Some coverage has described the animals as having “half-human” brains. That phrase is easily misunderstood. STAT reported that the description refers to tissue volume, not to a count of neurons. Stanford’s more specific figure is that human-origin tissue represented more than 90% of cortical tissue volume at three months.
Neither measure means that half the animal, half its brain cells, or its mental capacities were human. The transplanted tissue occupied a large share of a specially altered part of the mouse brain. It was not a normal human cortex and did not recreate the full organization of one.
The grafts were immature and did not have canonical cortical lamination, the layered architecture characteristic of a typical cortex, according to reporting by The Guardian and comments from senior author Sergiu Pașca to Inside Precision Medicine. There is also a basic biological timing problem: human neural development unfolds much more slowly than mouse development. That mismatch may constrain how the tissue integrates with a rapidly maturing mouse nervous system.
Stanford reported identifying human von Economo neurons in the grafts, a rare type of neuron associated with particular regions of the primate brain. The institution said such cells had not previously been generated in laboratory culture. Their presence is a potentially useful sign that the transplantation environment supported development of cell types difficult to obtain in a dish; it is not evidence that the grafts acquired human cortical function.
A test of oxygen deprivation, not a treatment result
As a proof of concept, the researchers exposed xenocortical mice to five hours of low oxygen. Stanford reported substantial injury in the human-origin cortical tissue, accompanied by gait and balance difficulties in the transplanted mice. Normal mice and apallial mice without the grafts were described as virtually unaffected under the experimental conditions.
Because oxygen exposure was deliberately manipulated, the experiment supports a causal conclusion about injury to the grafted tissue in this particular animal model. It does not identify what causes cerebral palsy, epilepsy, autism, schizophrenia or other conditions in people. Nor does it show that a drug, cell therapy or gene therapy can prevent such injury.
Pașca said the model could help investigate conditions including profound autism, epilepsy, schizophrenia and cerebral palsy, and could be used to test potential interventions. Those are prospective applications. Outside experts urged restraint about what the artificial system can reveal about ordinary human brain development. Madeline Lancaster of the MRC Laboratory of Molecular Biology told The Guardian that the model could be particularly useful for questions requiring a whole animal, while its implications for normal human development were less clear.
Ethical scrutiny will grow with the models
The study also raises questions that extend beyond its immediate findings. As human neural grafts grow larger and more connected to animal nervous systems, oversight must consider both animal welfare and whether an experiment could alter an animal’s capacities in ethically relevant ways. Emily Jackson, a London School of Economics law professor who chaired a Nuffield Council on Bioethics report, told The Guardian that the animals require close monitoring for welfare effects.
The present work offers no evidence that the mice developed human consciousness or human abilities. Still, its design makes the debate more concrete: it moves organoids from isolated laboratory cultures into a setting where they receive blood supply, sensory inputs and connections to a host nervous system. The scientific attraction of that setting—its closer approximation to living biology—is also why the ethical questions cannot be treated as settled.
For now, the model’s clearest contribution is technical. It gives researchers a larger, living environment in which human cortical tissue can grow and be experimentally stressed, while preserving a sharp boundary between a useful preclinical system and a human brain.